WO2022229817 - VACCINES COMPRISING VIRUS-LIKE PARTICLES DISPLAYING SARS-COV-2 ANTIGENS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2022/229817
Publication Date
03.11.2022
International Application No.
PCT/IB2022/053821
International Filing Date
25.04.2022
Title **
[English]
VACCINES COMPRISING VIRUS-LIKE PARTICLES DISPLAYING SARS-COV-2 ANTIGENS AND METHODS OF USE
[French]
VACCINS COMPRENANT DES PARTICULES PSEUDO-VIRALES PRÉSENTANT DES ANTIGÈNES DU SARS-COV-2 ET LEURS MÉTHODES D'UTILISATION
Applicants **
BAVARIAN NORDIC A/S
Philip Heymans Allé 3
2900 Hellerup, DK
ADAPTVAC APS
Ole Maaløes Vej 3
2200 N Copenhagen, DK
Inventors
VOLKMANN, Ariane
Bannweg 11
82346 Andechs, DE
BERTELSEN, Adam Frederik Sander
Ulspilsager 73
2791 Dragør, DK
Priority Data
63/181,117
28.04.2021
US
63/246,274
20.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1632 | |
| EPO | Filing, Examination | 8628 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 13910 |
Total: 25368 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides vaccines comprising virus-like particles displaying at least one SARS-CoV-2 antigen. Virus-like particles (VLPs) comprising AP205 protein display antigens such as the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein using a connection comprising a peptide tag and binding partner. The invention also relates to methods of treatment using the VLPs of the invention and use of the VLPs to treat and/or prevent infection with the SARS-CoV-2 virus and variants thereof. The invention further relates to medical uses of the VLPs in the prevention and/or amelioration of COVID-19 symptoms.[French]
L'invention concerne des vaccins comprenant des particules pseudo-virales présentant au moins un antigène du SARS-CoV-2. L'invention concerne également des particules pseudo-virales (PPV) comprenant des antigènes présentant une protéine AP205, comme le domaine de liaison au récepteur (DLR) de la protéine de spicule du SARS-CoV-2, utilisant une connexion comprenant une étiquette peptidique et un partenaire de liaison. L'invention concerne en outre des méthodes de traitement faisant appel aux PPV de l'invention et l'utilisation des PPV pour traiter et/ou prévenir une infection par le virus du SARS-CoV-2 et des variants de celui-ci. L'invention concerne enfin des utilisations médicales des PPV dans la prévention et/ou l'atténuation des symptômes de la COVID-19.